Abstract
Nonmyeloablative peripheral blood stem cell transplantation (PBSCT) is a novel therapeutic strategy for patients with malignant and non-malignant hematologic diseases. Infectious complications of this procedure have not been previously well described. Data on 12 patients transplanted at a tertiary care center were collected prospectively and verified retrospectively. Neutropenia developed in a third of patients, lasting for a median of 5 days. All patients developed some degree of graft-versus-host disease, as intended. Most patients achieved full chimerism by week 5. Bacterial infections occurred in two patients (17%). Cytomegalovirus (CMV) viremia occurred in five patients (42%) at a median of 80 days; none had received CMV prophylaxis. Viremia was associated with fever and fatigue in three patients, possible gastrointestinal involvement in one patient and was asymptomatic in one patient. All viremic patients responded to intravenous ganciclovir therapy. No fungal infections were documented. No patients died as a result of infection. The incidence of CMV viremia in our patients was high, but the incidence of invasive disease due to CMV was low. The best strategy to prevent CMV in patients undergoing nonmyeloablative PBSCT remains to be determined, but strategies employed in traditional allogeneic bone marrow transplantation should be considered in these patients. Bone Marrow Transplantation (2001) 28, 491–495.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Truitt RL, Johnson BD . Principles of graft-vs.-leukemia reactivity Biol Blood Marrow Transplant 1995 1: 61–68
Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia Blood 1989 73: 1720–1728
Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes Exp Hematol 1995 23: 1553–1562
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1999 17: 1958–1960
Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation New Engl J Med 2000 343: 750–758
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536
Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation Bone Marrow Transplant 2000 26: 251–255
Martino R, Romero P, Subira M et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry Bone Marrow Transplant 1999 24: 283–287
Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment Cancer 1981 47: 207–214
Meyers JD, Ljungman P, Fisher LD . Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia J Infect Dis 1990 162: 373–380
Adal KA, Avery RK . Prevention of cytomegalovirus infection after allogeneic bone marrow transplantation In: Bolwell BJ (ed.) Current Controversies in Bone Marrow Transplantation Humana Press: Totowa, NJ 1999 pp 295–315
Trenschel R, Ross S, Husing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following PBSCT Bone Marrow Transplant 2000 25: 665–672
Meyers JD, Flourny N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation J Infect Dis 1986 153: 478–488
Bowden RA, Meyers JD . Infections complicating bone marrow transplantation In: Rubin RH, Young LS (eds) Clinical Approach to Infection in the Compromised Host, 3rd edn Plenum: New York 1994 pp 601–628
Einsele H, Ehninger G, Steidle M et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation Blood 1993 82: 1672–1678
Takenaka K, Gondo H, Tanimoto K et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors Bone Marrow Transplant 1997 19: 241–248
Avery RK, Adal KA, Longworth DL, Bolwell BJ . A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy Bone Marrow Transplant 2000 26: 763–767
Prentice HG, Kho P . Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant Bone Marrow Transplant 1997 19: 135–152
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mossad, S., Avery, R., Longworth, D. et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 28, 491–495 (2001). https://doi.org/10.1038/sj.bmt.1703180
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703180
Keywords
This article is cited by
-
Aspergillosis in hematopoietic stem cell transplant recipients: Risk factors, prophylaxis, and treatment
Current Infectious Disease Reports (2009)
-
Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen
Bone Marrow Transplantation (2006)
-
Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias
Bone Marrow Transplantation (2005)
-
Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation
Bone Marrow Transplantation (2005)
-
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
Leukemia (2003)